Risk of Pending Shareholder Approval for the セルテクノロジー Share Exchange
First written in FY2019-Q3. 1 of 2 entries say "Mitigated", first in FY2019. Latest entry: FY2019.
No other company in this theme has enough history to compare yet.
- FY2019MitigatedAnnual report
「This share exchange was approved at extraordinary general meetings of shareholders held by the Company and Cell Technology on 12 March 2019, respectively, and became effective on 1 April 2019.」
Approval at the general meetings of shareholders was completed and the share exchange became effective, eliminating the risk premised on approval not being obtained. - FY2019-Q3First statedAnnual report
「With the objective of broadly developing the regenerative medicine business, which is a future growth driver, the Company resolved at a board meeting held on 17 January 2019 to make Cell Technology Co., Ltd. a wholly owned subsidiary through a share exchange. However, the agreement was subject to approval at the Company's extraordinary general meeting of shareholders scheduled for 12 March 2019, and if the proposal were rejected, it could have a material impact on the Company's business strategy and business plans.」
The acquisition of Cell Technology as a wholly owned subsidiary was subject to approval of the agreement at an extraordinary general meeting of shareholders, and the impact on business strategy and business plans if the proposal were rejected was disclosed as a new risk.